media – Page 163 – DrugDu- Global Leading Pharmaceutical & Medical Device Platform

Sleep Meds Don’t Work for 9 out of 10 People with Chronic Insomnia – Here’s What Does

Sleeplessness in America is on the rise, due to many external factors including increasingly negative news cycles, international conflicts and economic uncertainty. Collectively, these factors have caused more Americans to have more recurrent sleepless nights. When those nights reach three or more a week for three or more months, it’s considered chronic insomnia, which affects more than 25 million Americans. The condition can lead to both mental and physical health issues, ranging from trouble concentrating to sleep apnea and heart attacks. As we approach Sleep Awareness Week® 2024, which emphasizes the importance of sleep as a major contributor to a person’s overall health, it is also an important reminder to prioritize getting enough quality sleep. Sleep Awareness Week, which starts this year on March 10, always begins at the start of Daylight Saving Time. That’s when the clocks go forward by one hour and Americans lose an hour of sleep ...
- Source: drugdu
- 87
- March 11, 2024
Novo Nordisk Obesity Pill Flashes the Potential to Beat Wegovy in Weight Loss

An experimental Novo Nordisk obesity pill led to weight loss of 13.1% in a clinical trial, topping results posted in studies of the company’s approved injectable medication Wegovy. It’s early days and more testing is needed, but the preliminary data suggest that this pill has the potential to offer patients superior weight shedding in a more convenient oral formulation. Phase 1 data for the once-daily Novo Nordisk pill, amycretin, were presented Thursday during a company investor event. The study followed participants for 12 weeks. In that span, those who received a placebo lost 1.1% of their body weight. Wegovy, which is administered as a once-weekly injection, was not part of this clinical trial. Published clinical trial results for that drug show it led to weight loss of 5.9% measured at 12 weeks. Wegovy, whose main ingredient is the peptide semaglutide, offers one mechanism of action: activating the GLP-1 receptor to ...
- Source: drugdu
- 133
- March 11, 2024
BIO-THERA’s BAT8010 (ADC-HER2) for injection in combination with BAT1006 (HER2) for injection for the treatment of locally advanced or metastatic solid tumors was approved in clinical trial

BIO-THERA Biopharmaceutical Co., Ltd. (SSE: 688177) is a global science-based and innovative biopharmaceutical company based in Guangzhou, China, hereinafter referred to as “BIO-THERA” or the “Company”. The Company today announced that it has received a Notice of Approval of Drug Clinical Trial from the State Drug Administration of the People’s Republic of China (“SDA”), which approves the application for a clinical trial of the investigational drug BAT8010 for injection in combination with BAT1006 for injection for the treatment of locally advanced or metastatic solid tumors. BAT8010 consists of recombinant humanized anti-HER2 antibody and toxin small molecule topoisomerase I inhibitor, connected by self-developed shearable linker.BAT8010 has highly efficient anti-tumor activity, the toxin small molecule has strong cell membrane permeability, and it can be released and kill nearby cancer cells after ADC kills the cancer cells, generating the bystander effect, effectively overcoming the tumor cells’ heterogeneity of tumor cells. Meanwhile, BAT8010 has ...
- Source: drugdu
- 167
- March 10, 2024
Achieving first full year of profitability, and ushering in a new phase of high-quality development

Henlius (2696.HK) released a positive profit forecast. Based on the preliminary assessment of the unaudited consolidated management accounts for the year ended 31 December, 2023 (the “Reporting Period”) and the information currently available to the Board, it is expected that the company will record a profit for the year of no less than RMB500 million for the Reporting Period. This is the first time for Henlius to achieve full-year profits following the company’s achievement of its first half-year profits for the six months ended 30 June 2023. The full year of profitability is primarily contributed by the continuous growth in sales revenue of the company’s core products HANQUYOU and HANSIZHUANG, as well as cost reduction and efficiency improvement through refined management. Wenjie Zhang, Chairman and Executive Director of Henlius, said: “2023 is a milestone as we reported a full-year profit for the first time. Benefiting from the efficient synergy and ...
- Source: drugdu
- 125
- March 10, 2024
Landmark Clinical Approval for YOLT-201 Obtained by the NMPA

YolTech Therapeutics, a biotech company developing in vivo gene editing therapies to treat rare genetic diseases, today announced the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) has officially approved the YOLT-201 investigational new drug (IND) application for a Phase I study, marking that the drug candidate has officially entered the registration clinical development stage.. The first patient has been dosed with YOLT-201 in Investigator initiated trial(IIT) by the end of 2023, achieving promising preliminary efficacy and safety results. ATTR is a debilitating genetic disease, caused by misfolded transthyretin protein (TTR) forming amyloid fibrils and depositing in various organs and tissues in the body such as myocardium in the heart and peripheral nerves in the limbs. Depending on the mutation involved, hATTR can occur in people in their teens and 20s, though other forms are typically diagnosed in people over 50 years of age. YOLT-201 is ...
- Source: drugdu
- 89
- March 10, 2024
AACR 2024 | Ascentage Pharma to Present Three Preclinical Studies at 2024 American Association of Cancer Research Annual Meeting

Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, age-related diseases, and chronic hepatitis B (CHB), announced today that the latest results from three preclinical studies of the company’s novel drug candidates olverembatinib, MDM2-p53 inhibitor alrizomadlin, FAK/ALK/ROS1 tyrosine kinase inhibitor APG-2449, and EED inhibitor APG-5918, have been selected for presentations at the 2024 American Association of Cancer Research Annual Meeting (AACR 2024). These abstracts are now available on the AACR’s official website. The AACR annual meeting is one of the world’s largest and longest-standing scientific gatherings in the field of cancer research. Covering some of the most cutting-edge advances in all the areas of oncology research and innovation, the annual event attracts tremendous interest from the global cancer research community. This year’s AACR annual meeting will be held from April 5-10 2024, in San Diego, California, USA. These three preclinical abstracts from Ascentage Pharma include: ...
- Source: drugdu
- 97
- March 10, 2024
Akeso Announced the First Patient Dosed in Phase III Trial of Cadonilimab(PD-1/CTLA-4) Combined with Chemotherapy versus Tislelizumab Combined with Chemotherapy in First-line Treatment of PD-L1 negative NSCLC

HONG KONG, March 6, 2024 /PRNewswire/ — Akeso Inc. (“Akeso”, 9926. HK) announced the enrollment of the first patient in the registrational Phase III clinical study comparing Cadonilimab (PD-1/CTLA-4 bispecific antibody) combined with chemotherapy versus Tislelizumab (PD-1 antibody) combined with chemotherapy in the first-line treatment for patients with PD-L1 negative (PD-L1 TPS＜1%) non-small cell lung cancer (NSCLC) (NCT05990127). Lung cancer is a prevalent malignancy with significant global incidence and mortality rates. Retrospective studies conducted both worldwide and in China have revealed that PD-L1 negative expression is observed in up to 48% of patients with driver gene-negative NSCLC. Immunotherapy combined with chemotherapy stands as the first-line standard treatment for these patients. However, current treatment approaches provide limited survival benefits for PD-L1 negative patients. Hence, there exists a pressing clinical imperative for novel treatment modalities to enhance patients’ clinical outcomes. Compared to PD-1/PD-L1 monoclonal antibodies, PD-1 monoclonal antibody plus CTLA-4 monoclonal antibody ...
- Source: drugdu
- 95
- March 10, 2024
Chime Biologics Achieves ISO 27001 Certification to Strengthen Information Security in the CDMO Industry

After passing rigorous reviews on all the items of the control standards, Chime Biologics has obtained ISO 27001 certification, which is an internationally recognized standard for information security management. Dr. Jimmy Wei, President of Chime Biologics, said, “We are very proud to achieve ISO 27001 certification. As a global CDMO, Chime Biologics has always emphasized on protecting clients’ data and information and has comprehensive experience in data and information security. It is an important milestone that will further strengthen our global information security standards and our ability to be a trusted global partner.” Chime Biologics has three global ISO certifications, including ISO 14001 Environmental management systems certification, ISO 45001 Occupational health and safety management systems certification and ISO 27001 Information security management systems certification, demonstrating our full commitment in the environment protection, employees’ health and safety, as well as information security. About Chime Biologics Chime Biologics is a leading CDMO ...
- Source: drugdu
- 79
- March 10, 2024
Merck reports drop in net income for fiscal 2023

Despite declines in sales and EPS, Merck recorded a stable dividend of €2.20 per share for both 2023 and the preceding year. Merck’s EBITDA dropped by 15.6% from €6.504bn in 2022 to €5.489bn in 2023. Credit: Merck KGaA, Darmstadt, Germany and/or its affiliates. Merck KGaA (Merck) has reported a decline in financial performance for the fiscal year 2023, with net income attributable to shareholders falling by 15.1% to €2.82bn ($3.07bn), compared to €3.326bn in the previous year. Earnings per share (EPS) also saw a decrease of 15.2% to €6.49 from €7.65 in 2022. Group net sales experienced a downturn of 5.6% to €20.99bn from €22.23bn in 2022. The company has cited foreign exchange effects, particularly from the US dollar and the Chinese renminbi, as having a negative 4.1% impact on sales. Earnings before interest, taxes, depreciation and amortisation, a key financial indicator for business operations, also dropped by 15.6% from ...
- Source: drugdu
- 148
- March 9, 2024
The roadmap for generative AI in the pharma industry

AI remained one of the main talking points at CTS Europe, as the roadmap for generative AI was mapped out. In 2022, the launch of the generative Artificial Intelligence (AI) platform ChatGPT broke the record for the fastest-growing consumer application in history. Following the rapid adoption of AI technologies, the pharma sector is now exploring the capabilities and challenges of generative AI as it remains one of the key trends in the industry. However, despite the recent progress in the use of AI in real-world situations, we are still in the early stages of the AI roadmap, research director at GlobalData Josep Bori, at the recently concluded Clinical Trial Supply (CTS) Europe 2024 meeting. Generative AI is a technology capable of generating text, images or other data using generative models, often in response to prompts. Explaining how generative AI works, Bori said: “AI is trying to optimise the output to ...
- Source: drugdu
- 88
- March 9, 2024

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.